Compare Oklo Inc (OKLO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Oklo Inc trades at $44.41 (market cap $7.68B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| OKLO | XBI | |
|---|---|---|
Market Cap | $7.68B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $174.14 | $164.28 |
52-Week Low | $41.11 | $85.16 |
Enterprise Value | $5.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $41.51, up 0.97% today but remains in a significant downtrend with a 42% decline year-to-date. The stock shows bearish technical signals with negative profitability metrics including -8.87% ROE and consistent quarterly losses. Recent news highlights participation in a government nuclear power program for AI data centers, providing potential catalysts amid ongoing regulatory challenges and execution risks.
Despite analyst optimism with a $90.88 consensus target representing 119% upside, OKLO faces substantial execution and regulatory hurdles. The company burns significant cash with -$138.77M EBITDA while relying on financing activities. Long-term potential exists in nuclear energy demand, but near-term volatility and losses require careful risk assessment for investors.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
